Loading
Life sciences · Journal article
Pediatric Cardiology · September 23, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Improved childhood cancer survival has been accompanied by substantial late morbidity and mortality related to cardiotoxic cancer therapies. We conducted a retrospective study of childhood cancer survivors (CCS) diagnosed before age 21 and followed at The Children’s Hospital at Montefiore (CHAM). Collected data included demographics, cancer diagnosis and treatment details, medical history, and ambulation status. Initial and most recent echocardiograms obtained at CHAM were reviewed to calculate arterial elastance (Ea), end-systolic elastance (Ees), and ventricular-arterial coupling (VAC). Measurements were compared between CCS and healthy controls and between high- and low-risk CCS for cardiotoxicity using chi-square and Mann–Whitney tests, as appropriate. Multivariable regression assessed predictors of VAC. Sixty-nine CCS were included (median age at diagnosis 7.1 years, IQR 2.9–12.1). All participants had a left ventricular ejection fraction (LVEF) > 55% at follow-up. Compared with controls, CCS demonstrated significantly lower LVEF & LV mass ( p < 0.05). Although both Ea and Ees were lower in CCS, VAC ratios did not differ between CCS and controls. High-risk CCS had significantly lower Ees and VAC ratios ( p < 0.05). In multivariable analysis, cumulative anthracycline dose was independently associated with VAC ratio. Receiver operating characteristic (ROC) analyses demonstrated that VAC performed comparably to LVEF in identifying patients at high risk for cardiotoxicity. VAC serves as a complementary echocardiographic biomarker in CCS, particularly for those at increased cardiotoxic risk, and may offer mechanistic insights into heart failure development in this population.